28 September 2016 07:00
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive
Director, will step down from the Board of AstraZeneca PLC and as a member of
the Company’s Science Committee with effect from 1 October 2016. Dr Bargmann
recently accepted a new position as President of Chan Zuckerberg Science, part
of the Chan Zuckerberg Initiative.
Leif Johansson, AstraZeneca Chairman, said: “We congratulate Cori on her new
appointment and thank her for her contribution to AstraZeneca in the last 18
months. We are sorry to see her leave the AstraZeneca Board but fully
understand her decision to step down to focus on her new assignment.”
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on
the discovery, development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas – Respiratory and
Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company
is also active in inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Nick Stone Respiratory & Autoimmunity +44 203 749 5716
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Infection & Neuroscience +44 203 749 5711
US
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-
